Markers of cardiovascular risk in patients with antiphospholipid syndrome: A meta-analysis of literature studies

References

• Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
   PubMed Web of Science ®Google Scholar
• Mullen MT, Messé SR, Kasner SE, Sansing L, Husain MR, Norman GL, et al. Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a TIA cohort. Front Neurol. 2012;3:137.
   PubMedGoogle Scholar
• Mehrania T, Petri M. Epidemiology of the antiphospholipid syndrome. Amsterdam: Elsevier; 2009.
   Google Scholar
• Belizna CC, Richard V, Primard E, Kerleau JM, Cailleux N, Louvel JP, et al. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum. 2008;37:373–80.
   Google Scholar
• Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med. 2012;7:9–13.
   Google Scholar
• Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A. The clinical significance of antiphospholipid antibodies. Ann Med. 1997;29:159–63.
   Web of Science ®Google Scholar
• Tufano A, Guida A, Di Minno MN, De Gregorio AM, Cerbone AM, Di Minno G. Cardiovascular events in patients with antiphospholipid antibodies: strategies of prevention. Nutr Metab Cardiovasc Dis. 2010; 20:217–23.
   PubMedGoogle Scholar
• Koike T. Antiphospholipid antibodies in arterial thrombosis. Ann Med. 2000;32:27–31.
   Google Scholar
• Simon A, Chironi G, Levenson J. The performance of subclinical arterial disease detection as screening test for coronary heart disease. Hypertension. 2006;48:392–6.
   PubMed Web of Science ®Google Scholar
• Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther. 2002;16: 341–51.
   PubMed Web of Science ®Google Scholar
• de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109:III33–8.
   Web of Science ®Google Scholar
• O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340: 14–22.
   PubMed Web of Science ®Google Scholar
• Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol. 1997;146:483–94.
   PubMed Web of Science ®Google Scholar
• Calabia J, Torguet P, Garcia M, Garcia I, Martin N, Guasch B, et al. Doppler ultrasound in the measurement of pulse wave velocity: agreement with the Complior method. Cardiovasc Ultrasound. 2011;9:13.
   PubMed Web of Science ®Google Scholar
• Khan TH, Falahat AF, Niazi K. Critical review of the ankle brachial index. Curr Cardiol Rev. 2008;4:101–6.
   PubMedGoogle Scholar
• Ames PRJ, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64:315–17.
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Zain M, Bertolaccini ML, Sangle S, Khamashta MA, Hughes GRV, et al. Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis. 2006; 65:683–4.
   PubMedGoogle Scholar
• Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res. 2006;118:455–61.
   PubMed Web of Science ®Google Scholar
• Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA. 2009;302:1210–17.
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford). 2003; 42:645–51.
   PubMed Web of Science ®Google Scholar
• Bilora F, Boccioletti V, Girolami B, Zanon E, Armani M, Petrobelli F, et al. Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost. 2002;8:103–13.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed on 18th September 2014.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101–5.
   PubMed Web of Science ®Google Scholar
• Barón MA, Khamashta MA, Hughes GR, D’Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64:144–6.
   PubMedGoogle Scholar
• Margarita A, Batuca J, Scenna G, Alves JD, Lopez L, Iannaccone L, et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci. 2007;1108:475–80.
   PubMedGoogle Scholar
• Roch B, Kopprasch S, Pietzsch J, Schröder HE. Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Z Rheumatol. 2004; 63:331–7.
   Google Scholar
• Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi E, et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb Vasc Biol. 2014;34:661–8.
   Google Scholar
• Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2005;44:756–61.
   PubMedGoogle Scholar
• Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G, et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford). 2008;47: 1628–34.
   Google Scholar
• Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost. 2009;7:537–42.
   Google Scholar
• Bilora F, Sartori MT, Zanon E, Campagnolo E, Arzenton M, Rossato A. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology. 2009;60:104–7.
   Google Scholar
• Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, Barile L, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62:607–10.
   PubMed Web of Science ®Google Scholar
• Der H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus. 2007;16:497–503.
   PubMed Web of Science ®Google Scholar
• Caraba A, Şerban C, Mihǎescu R, Romoşan I. Subclinical atherosclerosis in primary antiphospholipid syndrome. Annals of the Romanian Society for Cell Biology. 2010;15:293–8.
   Google Scholar
• Ames PR, Tommasino C, Fossati G, Matsuura E, Margarita A, Saulino A, et al. Lymphocyte subpopulations and intima media thickness in primary antiphospholipd syndrome. Lupus. 2005;14:809–13.
   Google Scholar
• Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123:444–51.
   PubMed Web of Science ®Google Scholar
• Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun. 2010;34:105–10.
   PubMedGoogle Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from: www.cochrane-handbook.org. Accessed on 18th September 2014.
   Google Scholar
• Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012;38:497–505.
   PubMed Web of Science ®Google Scholar
• Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010;30:1014–26.
   PubMed Web of Science ®Google Scholar
• Jara LJ, Medina G, Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allergy Immunol. 2007;32:172–7.
   Web of Science ®Google Scholar
• Farmer-Boatwright MK, Roubey RA. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol. 2009;29:321–5.
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007;27:e309–10.
   Web of Science ®Google Scholar
• Galve-de Rochemonteix B, Kobayashi T, Rosnoblet C, Lindsay M, Parton RG, Reber G, et al. Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:563–74.
   Google Scholar
• Reverter JC, Tàssies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free proteins. Arterioscler Thromb Vasc Biol. 1996;16:1319–26.
   PubMed Web of Science ®Google Scholar
• Valesini G, Pittoni V. Treatment of thrombosis associated with immunological risk factors. Ann Med. 2000;32:41–5.
   Google Scholar
• George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2- glycoprotein I. Circulation. 1998;98:1108–15.
   PubMed Web of Science ®Google Scholar
• de Groot PG, Bouma B, Lutters BC, Derksen RH. Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I. Ann Med. 2000;32:32–6.
   Google Scholar
• Matsuura E, Koike T. Accelerated atheroma and anti-b2-glycoprotein I antibodies. Lupus. 2000;9:210–16.
   Google Scholar
• George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227–30.
   PubMed Web of Science ®Google Scholar
• Hörkkö S, Olee T, Mo L, Branch DW, Woods VL Jr, Palinski W, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta2- glycoprotein i and oxidized lowdensity lipoprotein. Circulation. 2001;103:941–6.
   PubMed Web of Science ®Google Scholar
• Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–7.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–41.
   PubMed Web of Science ®Google Scholar
• van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: The Rotterdam Study. Circulation. 2004;109:1089–94.
   PubMed Web of Science ®Google Scholar
• Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192:197–203.
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, de Faire U, et al. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol. 2013;33:2273–9.
   PubMed Web of Science ®Google Scholar
• Soltész P, Kerekes G, Dér H, Szücs G, Szántó S, Kiss E, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev. 2011; 10:416–25.
   PubMed Web of Science ®Google Scholar